VISEN Pharmaceuticals has issued a proxy circular convening an extraordinary general meeting (EGM) for 10:00 a.m. on 22 April 2026 at Room 1701, 1788 Square, 1788 West Nanjing Road, Jing’an District, Shanghai. Shareholders will vote on three ordinary resolutions that collectively formalise the group’s collaboration framework with several Ascendis entities.

1. Exclusive Licence Framework Agreement • Counterparties: VISEN Pharmaceuticals and the ELA Ascendis Subsidiaries • Execution date: 26 March 2026 • Scope: Approval, confirmation and ratification of the agreement, the revised 2026 annual cap and future annual caps for transactions under the arrangement. • Board authorisation: Directors will be empowered to take all steps deemed necessary to implement the licence framework.

2. 1st Commercial Supply Framework Agreement • Counterparties: VISEN HK and Ascendis Pharma Endocrinology Division • Execution date: 26 March 2026 • Scope: Approval of the revised 2026 CSA annual cap and future annual caps related to commercial supply of products. • Board authorisation: Directors will be granted the same implementation powers as above.

3. Supplemental Agreement to the 2nd Commercial Supply Framework Agreement • Counterparties: VISEN HK and Ascendis Europe • Execution date: 26 March 2026 • Scope: Ratification of the supplemental agreement and revised 2nd CSFA annual caps. • Board authorisation: Identical implementation authority to the previous resolutions.

Shareholders may appoint multiple proxies; completed proxy forms must reach Computershare Hong Kong Investor Services Ltd. by 10:00 a.m. on 20 April 2026. Completion of a proxy does not preclude shareholders from attending and voting in person.